Evidence map›Paper›PMID 34757067›Full record

ArticleThe Journal of investigative dermatology2022

Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated Melanomas.

Randie H Kim, Sofia Nomikou, Nicolas Coudray, George Jour, Zarmeena Dawood, Runyu Hong, Eduardo Esteva, Theodore Sakellaropoulos, Douglas Donnelly, Una Moran and 10 more

Abstract read
In one paragraph

Article in The Journal of investigative dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review of Molecular Technologies for Investigating Canine Cancer.Animals : an open access journal from MDPI · 2024
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Randie H KimRonald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA; Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.
Sofia NomikouDepartment of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Institute for Systems Genetics, Grossman School of Medicine, New York University, New York, New York, USA.
Nicolas CoudrayApplied Bioinformatics Laboratories, Grossman School of Medicine, New York University, New York, New York, USA; Department of Cell Biology, Skirball Institute of Biomolecular Medicine, Grossman School of Medicine, New York University, New York, New York, USA.
George JourRonald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA; Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Department of Pathology, Grossman School of Medicine, New York University, New York, New York, USA.
Zarmeena DawoodInterdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.
Runyu HongInstitute for Systems Genetics, Grossman School of Medicine, New York University, New York, New York, USA.
Eduardo EstevaDepartment of Biomedical Engineering, Tandon School of Engineering, New York University, New York, New York, USA.
Theodore SakellaropoulosDepartment of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.
Douglas DonnellyLaura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.
Una MoranInterdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.
Aristides HatzimemosRonald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA.
Jeffrey S WeberInterdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.
Narges RazavianDeparmtent of Radiology, Grossman School of Medicine, New York University, New York, New York, USA; Department of Population Health, Grossman School of Medicine, New York University, New York, New York, USA.
Iannis AifantisDepartment of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, Grossman School of Medicine, New York University, New York, New York, USA.
David FenyoInstitute for Systems Genetics, Grossman School of Medicine, New York University, New York, New York, USA; Department of Biochemistry and Molecular Pharmacology, Grossman School of Medicine, New York University, New York, New York, USA.
Matija SnuderlDepartment of Pathology, Grossman School of Medicine, New York University, New York, New York, USA.
Richard ShapiroInterdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Department of Surgery, Grossman School of Medicine, New York University, New York, New York, USA.
Russell S BermanInterdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA; Department of Surgery, Grossman School of Medicine, New York University, New York, New York, USA.
Iman OsmanRonald O. Perelman Department of Dermatology, Grossman School of Medicine, New York University, New York, New York, USA; Interdisciplinary Melanoma Cooperative Group, Grossman School of Medicine, New York University, New York, New York, USA.
Aristotelis TsirigosDepartment of Pathology, Grossman School of Medicine, New York University, New York, New York, USA; Applied Bioinformatics Laboratories, Grossman School of Medicine, New York University, New York, New York, USA. Electronic address: Aristotelis.Tsirigos@nyulangone.org.

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIRCHHOFF, TOMAS · 2019 to 2025
$12.5M
Proteogenomic Data Analysis for Cancer Systems Biology and Clinical TranslationU24CA210972 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DING, LI, FENYO, DAVID · 2016 to 2020
$3.3M
Acquisition of an Orbitrap Elite Mass Spectrometer with ETDS10OD010582 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI UEBERHEIDE, BEATRIX MAGDALENA · 2013 to 2013
$600k
Sandy Recovery Ventana Medical Systems Discovery XTS10OD018338 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHIRIBOGA, LUIS A · 2014 to 2014
$123k
NCI NIH HHS P30 CA016087NCI NIH HHS P50 CA225450NCI NIH HHS U24 CA210972NIH HHS S10 OD010582NIH HHS S10 OD018338
6 · The paper itself

Abstract

Image-based analysis as a method for mutation detection can be advantageous in settings when tumor tissue is limited or unavailable for direct testing. In this study, we utilize two distinct and complementary machine-learning methods of analyzing whole-slide images for predicting mutated BRAF. In the first method, whole-slide images of melanomas from 256 patients were used to train a deep convolutional neural network to develop a fully automated model that first selects for tumor-rich areas (area under the curve = 0.96) and then predicts for mutated BRAF (area under the curve = 0.71). Saliency mapping was performed and revealed that pixels corresponding to nuclei were the most relevant to network learning. In the second method, whole-slide images were analyzed using a pathomics pipeline that first annotates nuclei and then quantifies nuclear features, showing that mutated BRAF nuclei were significantly larger and rounder than BRAF‒wild-type nuclei. Finally, we developed a model that combines clinical information, deep learning, and pathomics that improves the predictive performance for mutated BRAF to an area under the curve of 0.89. Not only does this provide additional insights on how BRAF mutations affect tumor structural characteristics, but machine learning‒based analysis of whole-slide images also has the potential to be integrated into higher-order models for understanding tumor biology.

Indexed as

Deep LearningMelanomaCell NucleusHumansMutationProto-Oncogene Proteins B-rafBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID34757067
PMCPMC9054943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.